Brief: Adverum Biotechnologies Granted Orphan Drug Designation By FDA For Gene Therapy Candidate In Preclinical Development For The Treatment Of Blue Cone Monochromacy
04/01/2022 13:25
Jan 4 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES GRANTED ORPHAN DRUG DESIGNATION BY
FDA
FOR GENE THERAPY CANDIDATE IN PRECLINICAL DEVELOPMENT FOR THE
TREATMENT OF BLUE CONE MONOCHROMACY
* ADVERUM BIOTECHNOLOGIES INC - PLAN TO PRESENT PRECLINICAL
DATA
SUPPORTING PROOF OF CONCEPT OF ADVM-062 IN 1H2022
Source text for Eikon: ID:nGNXcf4fK0
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)